The Clinical Eye Research Unit (CERU) at the University of Wisconsin–Madison Department of Ophthalmology and Visual Sciences has been instrumental in the approval of a new treatment option for patients with exudative age-related macular degeneration (wet AMD).
clinical trial
IMVT TED
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Clinical Trial Offers Hope to Patients with Dry Age-Related Macular Degeneration
A current clinical trial could lead to approval of a first-ever treatment option for patients with geographic atrophy (GA) secondary to age-related macular degeneration, a progressive, irreversible, and devastating eye disease.
IZOKIBEP (IL-17A)
To assess the safety, tolerability, and immunogenicity of izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
GALE
To assess the long-term efficacy and safety of multiple intravitreal injections of APL-2 in subjects with geographic atrophy secondary to age-related macular degeneration.
CONCERTO
To determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
VILLA
To evaluate safety and tolerability of the Port Delivery System (PDS) in patients with neovascular age-related macular degeneration (nAMD).
HONU
The purpose of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced AMD stages.
Reading Centers in The Era of Artificial Intelligence: 2018 Retina Times Article
Barbara Blodi, MD, professor and medical director of the Fundus Photograph Reading Center (FPRC), and Amitha Domalpally, MD, research director of the FPRC were recently panelists for the Retina Times article, “Exploring the Role of …